A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Subscribe To Our Newsletter & Stay Updated
